pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 29·1 min read
save

Bristol Myers reaches a crossroads as a make-or-break year takes shape

Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by

Apr 29, 2026·read at Endpoints ↗

Chris Boerner, Bristol Myers Squibb CEO (Kevin Dietsch/Getty Images) April 29, 2026 11:33 AM EDT R&DPharmaIn Focus Bris­tol My­ers reach­es a cross­roads as a make-or-break year takes shape Max Gelman Senior Editor Bris­tol My­ers Squibb is fac­ing a bit of an iden­ti­ty cri­sis. CEO Chris Boern­er is near­ly two and a half years in­to his tenure, with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
92 words · retrieved Apr 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOL3BRISTOL MYERS SQUIBB2BRISTOL MYERS SQUIBB CO2

related stories

  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive
  • May 29Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksBioPharma Dive
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints
  • May 29Pfizer, Innovent strike $10B cancer drug dealBioPharma Dive
  • May 19STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much moreSTAT